The US Health Resources and Services Administration warned six drug manufacturers in recent letters that withholding or restricting 340B discounts to contract pharmacies violates the law and may be punishable by civil monetary penalties.
The letters, dated 17 May, mark the latest development in an ongoing dispute between manufacturers, 340B providers and the Health...





